Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Equity Average (2024 - 2026)

Prelude Therapeutics' Equity Average history spans 3 years, with the latest figure at $64.4 million for Q1 2026.

  • On a quarterly basis, Equity Average fell 45.1% to $64.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $64.4 million, a 45.1% decrease, with the full-year FY2025 number at $100.0 million, down 45.71% from a year prior.
  • Equity Average hit $64.4 million in Q1 2026 for Prelude Therapeutics, up from $63.6 million in the prior quarter.
  • Over the last five years, Equity Average for PRLD hit a ceiling of $223.9 million in Q1 2024 and a floor of $63.6 million in Q4 2025.
  • Historically, Equity Average has averaged $126.2 million across 3 years, with a median of $117.3 million in 2025.
  • Biggest five-year swings in Equity Average: crashed 60.33% in 2025 and later crashed 45.1% in 2026.
  • Tracing PRLD's Equity Average over 3 years: stood at $143.9 million in 2024, then crashed by 55.83% to $63.6 million in 2025, then rose by 1.3% to $64.4 million in 2026.
  • Business Quant data shows Equity Average for PRLD at $64.4 million in Q1 2026, $63.6 million in Q4 2025, and $67.2 million in Q3 2025.